Back
Open Access

Q&A - What have we learned from SGLT-2 inhibitors in heart failure?

logo

Session: What have we learned from SGLT-2 inhibitors in heart failure?
Topic: Other
Speaker: Professor S. Kang (Seoul, KR) Professor R. Fontes Carvalho (Vila Nova de Gaia, PT)
Sponsored by Boehringer Ingelheim
Event: ESC Asia with APSC & AFC 2020

Congress Presentation

About the speakers

Professor Seok Min Kang

Yonsei University, Seoul (Korea (Republic of))
5 presentations
0 follower

Professor Ricardo Fontes Carvalho

Hospital Center of Vila Nova de Gaia/Espinho, Vila Nova de Gaia (Portugal)
27 presentations
7 followers

3 more presentations in this session

Welcome/Opening - What have we learned from SGLT-2 inhibitors in heart failure?

Speaker: Professor S. Kang (Seoul, KR)

Access
Video
Thumbnail

What have we learned from SGLT-2 Inhibitors in Heart Failure?

Speaker: Professor R. Fontes Carvalho (Vila Nova de Gaia, PT)

Access
Video
Thumbnail

Closing/Conclusion - What have we learned from SGLT-2 inhibitors in heart failure?

Speaker: Professor S. Kang (Seoul, KR)

Access
Video
Thumbnail

Access the full session

What have we learned from SGLT-2 inhibitors in heart failure?

Speakers: Professor S. Kang, Professor R. Fontes Carvalho, Professor S. Kang, Professor R. Fontes Carvalho, Professor S. Kang
Access
Video
Thumbnail

About the event

Image

ESC Asia with APSC & AFC 2020

3 December - 5 December 2020

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb